



Insights Into Treatment Pathways of Hodgkin Lymphoma

November 19, 2022

Chair: Krish Patel, MD

Moderator: Sushil Bhardwaj, MD

AGENDA

Time (CT)	Topic
1.45 PM – 2.00 PM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview • ARS questions
2.00 PM – 3.30 PM (45-min presentation; 45-min discussion)	First-Line Treatment of Hodgkin Lymphoma <ul style="list-style-type: none"> • Overview of current and recent data <ul style="list-style-type: none"> – Factors guiding first-line therapy <ul style="list-style-type: none"> ▪ Impact of favorable vs unfavorable factors with and without bulky disease (stage III–IV) ▪ Impact of patient age on therapy approach (≥60 years vs <60 years) <ul style="list-style-type: none"> • Treatment of elderly population ▪ Combined-modality therapy vs chemotherapy alone ▪ Incorporation of brentuximab vedotin into treatment paradigm ▪ ECHELON-1 trial results <ul style="list-style-type: none"> • Efficacy • OS benefit of A + AVD vs AVBD • Actual OS benefit and general endpoints • PFS, mortality, safety • Resolution of peripheral neuropathy (PN) <ul style="list-style-type: none"> – Six-year PN resolution data • Role of G-CSF and neutropenia <ul style="list-style-type: none"> – Is there a prophylactic role? ▪ PET/CT restaging and Deauville criteria • Reaction and discussion
3.30 PM – 3.40 PM (10 min)	BREAK
3.40 PM – 4.30 PM (20-min presentation; 30-min discussion)	Management of Relapsed/Refractory Hodgkin Lymphoma <ul style="list-style-type: none"> • Baseline ARS questions • Overview of current data <ul style="list-style-type: none"> – Factors guiding second-line and subsequent therapy – Impact of prior therapy

	<ul style="list-style-type: none">- PET/CT restaging and Deauville criteria- High-dose therapy and autologous stem cell rescue- Transplant (autologous or allogeneic)• Reaction and discussion
4.30 PM – 4.45 PM (15 min)	Key Takeaways and Meeting Evaluation